Ionis Ribo enters a collaboration for RNA targeted Therapeutics

Ionis Pharmaceuticals announced its collaboration and license agreement with Suzhou Ribo Life Science Co., Ltd. (Ribo) to develop and commercialize RNA-targeted therapeutics in China.

According to the agreement Ionis granted Ribo a license for the right to commercialize in China two Ionis Generation 2+ antisense drugs in metabolic disease and cancer and an option to license a third pre-specified Generation 2+ antisense drug. In addition, Ribo will be responsible for conducting a multi-year research and drug discovery program to identify drugs that utilize Ionis’ ssRNAi technology. Ionis will receive an undisclosed up-front payment and equity in Ribo. Ionis retains the rights to develop and commercialize ssRNAi technology and all drugs under the collaboration outside of China.

Senior vice president of drug discovery and franchise leader for oncology and rare diseases at Ionis Pharmaceuticals, Brett Monia said that the need for new medicines in China is growing rapidly, especially for metabolic diseases and certain genetically-defined cancers. Ribo is the ideal partner for them in China. Ribo has made excellent progress in its RNAi therapeutic programs and we believe they will benefit from rebo drug development and regulatory expertise in China. They believe that their partnership with Ribo maximizes the value of their drugs in this collaboration by leveraging the clinical data generated in China to support the overall global development plan for each drug.

Ribo founder and Chairman, Liang Zicai said that they are committed to advancing new RNA-targeted therapeutics, like RNAi and antisense, to patients with high unmet medical need in China. Ionis has made significant breakthroughs showing that chemically modified single-stranded oligonucleotides can activate the RNAi pathway. They believe that this work is the foundation for a robust drug discovery platform that takes advantage of using single-stranded RNA-like antisense drugs that harness the power of the RNAi pathway. They are excited by the opportunity to contribute our expertise and resources to advancing this promising technology.

Ribo may exercise its option to license each drug by paying Ionis a license fee. For each drug that Ribo licenses, Ribo will be responsible for all development and commercialization activities and costs in China. Ionis is eligible to receive development, regulatory and commercial milestone payments as each drug advances. In addition, Ionis is eligible to receive royalties on net sales of each drug.

Ribo will provide Ionis a royalty-free license to the data and intellectual property created under the collaboration.